A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Inclusion Criteria:

- Male and female subjects ages >18 years of age, inclusive.

- History of plasma TG concentration ≥890 mg/dl (10 mmol/L) or history of lactescent
plasma in the fasting state.

- Fasting TG ≥ 750 mg/dL (8.5 mmol/L) at day -7 or repeat of day -7 one week later for
those failing to qualify initially and thought likely to qualify on repeat
examination prior to randomization.

Exclusion Criteria:

- Treatment with Omega-3 fatty acids or niacin or fibrates within 8 weeks of screening.

- Patients with confirmed Familial Chylomicronemia Syndrome (FCS) with
hyperlipoproteinemia (HLP) Type-I diagnosis or known to be homozygotes or compound
heterozygotes for mutations in HLP Type I-causing genes (such as LPL, apoCII,
CPIHBP1, or LMF1) prior to screening.

- Pancreatitis within 3 months prior to screening.

- Uncontrolled type 2 diabetes (T2DM) (as defined by an HbA1c value of ≥8.0% at
screening)

- BMI > 40 or history of bariatric surgery.

- Nephrotic syndrome, Type 1 diabetes, HIV, HCV or HBV positive.

- Estimated Glomerular Filtration Rate (eGFR) < 60 ml/min/1.73m2

Other protocol defined inclusion/exclusion criteria may apply